Viking Therapeutics Inc (VKTX)

75.05 -1.38 (-1.81%) USD  |  NASDAQ  |  May 02, 12:23
More

Viking Therapeutics Research and Development Expense (Quarterly): 24.10M for March 31, 2024

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2012. Upgrade now.
Date Value
March 31, 2024 24.10M
December 31, 2023 20.50M
September 30, 2023 18.38M
June 30, 2023 13.92M
March 31, 2023 11.01M
December 31, 2022 16.18M
September 30, 2022 11.96M
June 30, 2022 13.54M
March 31, 2022 12.56M
December 31, 2021 9.847M
September 30, 2021 10.80M
June 30, 2021 12.80M
March 31, 2021 11.54M
December 31, 2020 9.049M
September 30, 2020 7.116M
June 30, 2020 7.78M
March 31, 2020 7.987M
December 31, 2019 6.451M
September 30, 2019 5.279M
June 30, 2019 7.333M
March 31, 2019 4.496M
December 31, 2018 5.089M
Date Value
September 30, 2018 5.687M
June 30, 2018 5.221M
March 31, 2018 3.043M
December 31, 2017 3.033M
September 30, 2017 3.465M
June 30, 2017 3.716M
March 31, 2017 3.528M
December 31, 2016 2.648M
September 30, 2016 2.105M
June 30, 2016 2.371M
March 31, 2016 1.877M
December 31, 2015 3.219M
September 30, 2015 2.508M
June 30, 2015 1.101M
March 31, 2015 0.139M
December 31, 2014 0.1428M
September 30, 2014 0.7886M
June 30, 2014 21.24M
March 31, 2014 0.05M
June 30, 2013 0.0033M
March 31, 2013 0.0006M
December 31, 2012 0.0689M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

5.279M
Minimum
Sep 2019
24.10M
Maximum
Mar 2024
11.91M
Average
11.27M
Median

Research and Development Expense (Quarterly) Benchmarks

Eli Lilly and Co 2.523B
Pfizer Inc 2.815B
Madrigal Pharmaceuticals Inc 70.64M
Akero Therapeutics Inc 53.39M
Terns Pharmaceuticals Inc 17.46M